NASDAQ:KLDO

Kaleido Biosciences Competitors

$6.08
-0.09 (-1.46 %)
(As of 04/20/2021 04:30 PM ET)
Add
Compare
Today's Range
$5.85
Now: $6.08
$6.21
50-Day Range
$6.50
MA: $8.71
$10.99
52-Week Range
$5.04
Now: $6.08
$20.50
Volume216,580 shs
Average Volume335,148 shs
Market Capitalization$258.20 million
P/E RatioN/A
Dividend YieldN/A
Beta0.02

Competitors

Kaleido Biosciences (NASDAQ:KLDO) Vs. CNTB, BOLT, FDMT, GRCL, PHVS, and PHAR

Should you be buying KLDO stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Kaleido Biosciences, including Connect Biopharma Holdings Limited American Depositary Shares (CNTB), Bolt Biotherapeutics (BOLT), 4D Molecular Therapeutics (FDMT), Gracell Biotechnologies (GRCL), Pharvaris B.V. (PHVS), and Pharming Group (PHAR).

Kaleido Biosciences (NASDAQ:KLDO) and Connect Biopharma Holdings Limited American Depositary Shares (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Profitability

This table compares Kaleido Biosciences and Connect Biopharma Holdings Limited American Depositary Shares' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kaleido BiosciencesN/AN/AN/A
Connect Biopharma Holdings Limited American Depositary SharesN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Kaleido Biosciences and Connect Biopharma Holdings Limited American Depositary Shares, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kaleido Biosciences11402.50
Connect Biopharma Holdings Limited American Depositary Shares00303.00

Kaleido Biosciences presently has a consensus target price of $17.90, suggesting a potential upside of 194.41%. Connect Biopharma Holdings Limited American Depositary Shares has a consensus target price of $29.50, suggesting a potential upside of 72.72%. Given Kaleido Biosciences' higher probable upside, equities research analysts plainly believe Kaleido Biosciences is more favorable than Connect Biopharma Holdings Limited American Depositary Shares.

Institutional and Insider Ownership

79.9% of Kaleido Biosciences shares are held by institutional investors. 10.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Kaleido Biosciences and Connect Biopharma Holdings Limited American Depositary Shares' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido BiosciencesN/AN/AN/A($3.36)-1.81
Connect Biopharma Holdings Limited American Depositary SharesN/AN/AN/AN/AN/A

Summary

Kaleido Biosciences beats Connect Biopharma Holdings Limited American Depositary Shares on 4 of the 5 factors compared between the two stocks.

Kaleido Biosciences (NASDAQ:KLDO) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Profitability

This table compares Kaleido Biosciences and Bolt Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kaleido BiosciencesN/AN/AN/A
Bolt BiotherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Kaleido Biosciences and Bolt Biotherapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kaleido Biosciences11402.50
Bolt Biotherapeutics00403.00

Kaleido Biosciences presently has a consensus price target of $17.90, suggesting a potential upside of 194.41%. Bolt Biotherapeutics has a consensus price target of $41.00, suggesting a potential upside of 68.86%. Given Kaleido Biosciences' higher probable upside, research analysts clearly believe Kaleido Biosciences is more favorable than Bolt Biotherapeutics.

Institutional & Insider Ownership

79.9% of Kaleido Biosciences shares are held by institutional investors. 10.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Kaleido Biosciences and Bolt Biotherapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido BiosciencesN/AN/AN/A($3.36)-1.81
Bolt BiotherapeuticsN/AN/AN/AN/AN/A

Summary

Kaleido Biosciences beats Bolt Biotherapeutics on 3 of the 4 factors compared between the two stocks.

Kaleido Biosciences (NASDAQ:KLDO) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Profitability

This table compares Kaleido Biosciences and 4D Molecular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kaleido BiosciencesN/AN/AN/A
4D Molecular TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Kaleido Biosciences and 4D Molecular Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kaleido Biosciences11402.50
4D Molecular Therapeutics01202.67

Kaleido Biosciences presently has a consensus price target of $17.90, suggesting a potential upside of 194.41%. 4D Molecular Therapeutics has a consensus price target of $45.50, suggesting a potential upside of 41.66%. Given Kaleido Biosciences' higher probable upside, research analysts clearly believe Kaleido Biosciences is more favorable than 4D Molecular Therapeutics.

Institutional & Insider Ownership

79.9% of Kaleido Biosciences shares are held by institutional investors. 10.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Kaleido Biosciences and 4D Molecular Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido BiosciencesN/AN/AN/A($3.36)-1.81
4D Molecular TherapeuticsN/AN/AN/AN/AN/A

Summary

Kaleido Biosciences beats 4D Molecular Therapeutics on 4 of the 5 factors compared between the two stocks.

Kaleido Biosciences (NASDAQ:KLDO) and Gracell Biotechnologies (NASDAQ:GRCL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Profitability

This table compares Kaleido Biosciences and Gracell Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kaleido BiosciencesN/AN/AN/A
Gracell BiotechnologiesN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Kaleido Biosciences and Gracell Biotechnologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kaleido Biosciences11402.50
Gracell Biotechnologies00403.00

Kaleido Biosciences presently has a consensus price target of $17.90, suggesting a potential upside of 194.41%. Gracell Biotechnologies has a consensus price target of $34.50, suggesting a potential upside of 179.58%. Given Kaleido Biosciences' higher probable upside, research analysts clearly believe Kaleido Biosciences is more favorable than Gracell Biotechnologies.

Institutional & Insider Ownership

79.9% of Kaleido Biosciences shares are held by institutional investors. 10.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Kaleido Biosciences and Gracell Biotechnologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido BiosciencesN/AN/AN/A($3.36)-1.81
Gracell BiotechnologiesN/AN/AN/AN/AN/A

Summary

Kaleido Biosciences beats Gracell Biotechnologies on 3 of the 4 factors compared between the two stocks.

Kaleido Biosciences (NASDAQ:KLDO) and Pharvaris B.V. (NASDAQ:PHVS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Profitability

This table compares Kaleido Biosciences and Pharvaris B.V.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kaleido BiosciencesN/AN/AN/A
Pharvaris B.V.N/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Kaleido Biosciences and Pharvaris B.V., as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kaleido Biosciences11402.50
Pharvaris B.V.01302.75

Kaleido Biosciences presently has a consensus price target of $17.90, suggesting a potential upside of 194.41%. Pharvaris B.V. has a consensus price target of $47.50, suggesting a potential upside of 104.65%. Given Kaleido Biosciences' higher probable upside, research analysts clearly believe Kaleido Biosciences is more favorable than Pharvaris B.V..

Institutional & Insider Ownership

79.9% of Kaleido Biosciences shares are held by institutional investors. 10.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Kaleido Biosciences and Pharvaris B.V.'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido BiosciencesN/AN/AN/A($3.36)-1.81
Pharvaris B.V.N/AN/AN/AN/AN/A

Summary

Kaleido Biosciences beats Pharvaris B.V. on 4 of the 5 factors compared between the two stocks.

Pharming Group (NASDAQ:PHAR) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Profitability

This table compares Pharming Group and Kaleido Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pharming GroupN/AN/AN/A
Kaleido BiosciencesN/AN/AN/A

Valuation and Earnings

This table compares Pharming Group and Kaleido Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharming GroupN/AN/AN/AN/AN/A
Kaleido BiosciencesN/AN/AN/A($3.36)-1.81

Analyst Recommendations

This is a summary of current ratings and target prices for Pharming Group and Kaleido Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pharming Group0000N/A
Kaleido Biosciences11402.50

Kaleido Biosciences has a consensus price target of $17.90, suggesting a potential upside of 194.41%. Given Kaleido Biosciences' higher probable upside, analysts plainly believe Kaleido Biosciences is more favorable than Pharming Group.

Institutional & Insider Ownership

79.9% of Kaleido Biosciences shares are held by institutional investors. 10.0% of Kaleido Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Kaleido Biosciences beats Pharming Group on 4 of the 4 factors compared between the two stocks.


Kaleido Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.7$17.08-0.9%$962.29 millionN/A0.00Analyst Report
News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$24.34-0.2%$882.77 millionN/A0.00
FDMT
4D Molecular Therapeutics
1.3$31.93-3.4%$880.90 millionN/A0.00
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$12.34-3.7%$839.21 millionN/A0.00Gap Up
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$23.08-12.7%$828.16 millionN/A0.00
Pharming Group logo
PHAR
Pharming Group
0.0$12.90-0.4%$827.27 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$22.28-5.7%$737.78 millionN/A0.00
FNCH
Finch Therapeutics Group
2.0$14.23-8.9%$730.28 millionN/A0.00Analyst Report
News Coverage
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$15.76-1.6%$630.05 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$13.27-0.9%$517.26 millionN/A0.00News Coverage
SGTX
Sigilon Therapeutics
1.4$16.00-0.4%$506.09 millionN/A0.00Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$10.84-3.5%$482.45 millionN/A0.00Gap Up
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.06-7.9%$435.28 millionN/A0.00
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$16.78-1.9%$429.64 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$18.46-0.5%$417.84 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$12.98-1.7%$403.76 millionN/A0.00News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$13.30-2.0%$400.10 millionN/A0.00Gap Up
PRTG
Portage Biotech
0.0$28.15-4.4%$355.24 millionN/A0.00Gap Up
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$4.91-5.7%$268.57 millionN/A-2.61
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$9.70-1.4%$245.04 millionN/A0.00
VINC
Vincerx Pharma
1.0$16.43-4.8%$240.80 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$9.22-7.2%$188.90 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
LBPH
Longboard Pharmaceuticals
1.9$10.14-0.1%$171.37 millionN/A0.00Quiet Period Expiration
GANX
Gain Therapeutics
1.7$13.50-3.5%$158.29 millionN/A0.00Analyst Report
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$22.31-1.6%$152.49 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$7.16-4.3%$131.51 millionN/A0.00News Coverage
Gap Up
LGVN
Longeveron
0.3$6.02-3.5%$118.10 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$30.39-13.5%$80.60 millionN/A0.00News Coverage
UPC
Universe Pharmaceuticals
0.0$3.44-3.2%$77.21 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$15.37-2.1%$58.78 millionN/A0.00Decrease in Short Interest
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.03-3.2%$52.17 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.17-8.1%$46.57 millionN/A0.00
VIRX
Viracta Therapeutics
1.7$7.77-2.8%$39.06 millionN/A0.00
VYNT
Vyant Bio
0.0$3.35-3.3%$38.08 millionN/A0.00Gap Up
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.06-4.9%$34.28 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.32-1.6%$29.90 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.01-6.2%$21.07 millionN/A0.00News Coverage
BCTX
BriaCell Therapeutics
0.0$2.89-8.0%$2.41 millionN/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.52-1.6%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.07-7.1%$0.00N/A0.00Gap Up
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06-0.0%$0.00N/A0.00
BMEA
Biomea Fusion
0.0$16.79-1.3%$0.00N/A0.00High Trading Volume
Gap Up
RXRX
Recursion Pharmaceuticals
0.0$29.94-6.5%$0.00N/A0.00News Coverage
Gap Up
RPHM
Reneo Pharmaceuticals
0.3$12.87-1.2%$0.00N/A0.00
SCPS
Scopus BioPharma
1.4$7.58-1.6%$0.00N/A0.00
VECT
VectivBio
0.0$15.25-0.0%$0.00N/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.